Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

IGI-Myeloma-Study